Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - candesartan cilexetil, quantity: 4 mg - tablet - excipient ingredients: lactose monohydrate; croscarmellose sodium; magnesium stearate; carrageenan; povidone; maize starch - treatment of hypertension. . treatment of patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction less than or equal to 40percent) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - candesartan cilexetil, quantity: 32 mg - tablet - excipient ingredients: maize starch; magnesium stearate; titanium dioxide; povidone; lactose monohydrate; iron oxide red; carrageenan; croscarmellose sodium - treatment of hypertension. . treatment of patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction less than or equal to 40percent) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - candesartan cilexetil, quantity: 8 mg - tablet - excipient ingredients: lactose monohydrate; carrageenan; maize starch; povidone; iron oxide red; croscarmellose sodium; titanium dioxide; magnesium stearate - treatment of hypertension. . treatment of patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction less than or equal to 40percent) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - candesartan cilexetil, hydrochlorothiazide - tablets - 16/12.5 milligram - angiotensin ii antagonists and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - candesartan cilexetil hydrochlorothiazide - tablets - 8/12.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - candesartan cilexetil, hydrochlorothiazide - tablets - 16/12.5 milligram - angiotensin ii antagonists and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - candesartan cilexetil, hydrochlorothiazide - tablets - 8/12.5 milligram - angiotensin ii antagonists and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - candesartan cilexetil; hydrochlorothiazide - tablet - 32 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; candesartan and diuretics

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’

United States - English - NLM (National Library of Medicine)

solco healthcare llc - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joi